BioSpace News Archive

Ventus Therapeutics announced today that it has been awarded a $150,000 grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF ™ for the Treatment of Presbyopia.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27 in Boston.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company TM , today announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced the presentation of two posters related to the company’s novel molecular glue, SP-3164, at the American Association for Cancer Research (AACR) Annual Meeting.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the publication of preclinical data for the company’s small interfering RNA (siRNA) designs in the journal Nucleic Acids Research.

PLT Health Solutions, Inc. announced that it has partnered with Nano Pharmaceuticals Labs, LLC ( Denver, CO ) to market its portfolio of targeted release ingredients on a global basis.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announced that CT041, an autologous CAR T-cell product candidate against the protein Claudin18.2 (CLDN18.2), has achieved IND clearance from the National Medical Products Administration (NMPA) for the postoperative adjuvant therapy of CLDN18.2 positive pancreatic cancer (PC).

Corza Medical announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical professionals worldwide, to the U.S. market effective April 2023.